Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | ESRRA | P11474 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058875 | 0.84 | ESR1 (0.61) | ESR1ESR2ESRRAEGFRMIF | |
| SCHEMBL14924053 | 0.79 | EGFR (0.51) | ESR1ESR2ESRRAEGFRPOLB | |
| SCHEMBL2592130 | 0.79 | EGFR (0.62) | ESR1ESR2ESRRAEGFRMIF | |
| SCHEMBL15026344 | 0.76 | EGFR (0.56) | EGFRMAPTTP53 | |
| SCHEMBL2588545 | 0.72 | EGFR (0.73) | ESR1ESR2ESRRAEGFR | |
| SCHEMBL2582121 | 0.68 | ESR2 (0.56) | ESR1ESR2ESRRAEGFR | |
| SCHEMBL14924051 | 0.67 | EGFR (0.54) | ESR1ESR2ESRRAEGFRPOLB | |
| SCHEMBL18381973 | 0.66 | EGFR (0.35) | EGFR | |
| SCHEMBL14924128 | 0.66 | MIF (0.41) | MIFPOLBMAPTLMNATP53 | |
| SCHEMBL4274776 | 0.65 | ESR1 (0.44) | ESR1ESR2ESRRAMIFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | VA Long Beach Healthcare System (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | ESR1 28/4885ESR2 4/4885ESRRA 3/4885 |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP3, NCOR1, NR3C2 | ESR1 375/4885ESR2 42/4885ESRRA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.